Business Description
Ceryvyn Therapeutics Ltd
ISIN : US68386J2087
Share Class Description:
CYVNY: ADRTotal Employee Number:
10Description
Ceryvyn Therapeutics Ltd is an Australian biotechnology company developing a biologic therapy for the rare disease LAM (lymphangioleiomyomatosis). It is engaged in the investigation of CYV-101 as a potential treatment for Lymphangioleiomyomatosis (LAM). It operates in one segment, being the biotechnology and healthcare industry in Australia.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.93 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 6.62 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year FCF Growth Rate | 72 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6092.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.1 | |||||
9-Day RSI | 48.21 | |||||
14-Day RSI | 48.46 | |||||
3-1 Month Momentum % | -12.35 | |||||
6-1 Month Momentum % | -4.35 | |||||
12-1 Month Momentum % | -99.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.78 | |||||
Quick Ratio | 13.78 | |||||
Cash Ratio | 12.96 | |||||
Days Sales Outstanding | 30042.31 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -606264.1 | |||||
Net Margin % | -643964.1 | |||||
EBITDA Margin % | -486556.41 | |||||
FCF Margin % | -629104 | |||||
OCF Margin % | -629056 | |||||
ROE % | Neg. Equity | |||||
ROA % | -423.4 | |||||
ROIC % | -130.73 | |||||
ROC (Joel Greenblatt) % | -141714.18 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 0.36 | |||||
Price-to-Owner-Earnings | 0.04 | |||||
PB Ratio | 0.45 | |||||
Price-to-Tangible-Book | 0.46 | |||||
EV-to-EBIT | -0.29 | |||||
EV-to-EBITDA | -0.29 | |||||
EV-to-Revenue | 1395.28 | |||||
EV-to-Forward-Revenue | 102.03 | |||||
EV-to-FCF | -0.22 | |||||
Price-to-GF-Value | 0.01 | |||||
Price-to-Graham-Number | 0.05 | |||||
| Price-to-Net-Current-Asset-Value | 0.46 | |||||
| Price-to-Net-Cash | 0.46 | |||||
Earnings Yield (Greenblatt) % | -344.83 | |||||
FCF Yield % | -1789.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CYVNY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ceryvyn Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.025 | ||
| EPS (TTM) ($) | -1.044 | ||
| Beta | 2.7783 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.31 | ||
| Volatility % | 136.88 | ||
| 14-Day RSI | 48.46 | ||
| 14-Day ATR ($) | 0.0036 | ||
| 20-Day SMA ($) | 0.02308 | ||
| 12-1 Month Momentum % | -99.35 | ||
| 52-Week Range ($) | 0.0017 - 3.41 | ||
| Shares Outstanding (Mil) | 171 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ceryvyn Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ceryvyn Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-03-02 | In 168 days | ||
| Annual report for 2026 | 2026-09-15 | 0.02 (+0.00%) | ||
| Fourth quarter earnings results for 2026 | 2026-09-04 | 0.02 (+16.00%) | ||
| Second quarter earnings results for 2026 | 2026-03-02 | 0.02 (-60.94%) | ||
| Annual report for 2025 | 2025-09-15 | 3.41 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-29 | 3.41 (+0.00%) | ||
| Oppenheimer’s 35th Annual Healthcare Life Sciences Conference | 2025-02-11 10:00 | 5.54 (-2.12%) | ||
| Opthea Investor Day | 2025-02-05 16:30 | 5.33 (-1.30%) | ||
| Opthea Investor Day | 2025-02-03 16:30 | 5.56 (-2.11%) | ||
| 43rd Annual J.P. Morgan Healthcare Conference | 2025-01-15 17:15 | 3.82 (+4.66%) |
Show
Entries
Ceryvyn Therapeutics Ltd Frequently Asked Questions
What is Ceryvyn Therapeutics Ltd(CYVNY)'s stock price today?
The current price of CYVNY is $0.02. The 52 week high of CYVNY is $3.41 and 52 week low is $0.00.
When is next earnings date of Ceryvyn Therapeutics Ltd(CYVNY)?
The next earnings date of Ceryvyn Therapeutics Ltd(CYVNY) is 2027-03-02 Est..
Does Ceryvyn Therapeutics Ltd(CYVNY) pay dividends? If so, how much?
Ceryvyn Therapeutics Ltd(CYVNY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers